Currus Biologics

Backed by Main Sequence · currusbio.com ↗

Founded: 2020
Head office: Melbourne, Australia
Founder: Sam Cobb CEO

Currus Biologics develops CAR-T cell therapies, a treatment that modifies a patient's immune cells to attack cancer. It is focused on solid tumours, which are harder to treat this way than blood cancers. Its approach is built on a technology it calls BEAT, and it aims to improve treatment outcomes in oncology.

Why it matters in Australia: Main Sequence has backed Currus Biologics since 2025.

Backed by

Main Sequence first invested 2025 Main Sequence profile ↗

Similar companies

Accretion Bio To cure disease, you first have to see it. We watch single molecules move inside living neurons in real time - revealing how brain disease begins, and how to stop it. Antler Australia Andromeda Where technology meets empathy – pioneering the future of human-robot interaction. Main Sequence Everlab Marc, Sam, Anshul and Steven are on a mission to help people live longer, healthier lives. AirTree 9 roles in Australia Auggie Auggie is the AI patient retention platform that turns dormant dental patient lists into recovered revenue. Antler Australia indi One connected system for child development care Antler Australia Minikai Your AI ally in disability and aged care. Antler Australia

The summary above was written with AI from the company's own site and its backers' listings, and checked by an editor. Backers, years and rounds are as each fund lists them. Founded year, head office, founders and offices are as crunchbase.com, pitchbook.com and Main Sequence state them. Open roles are read daily from the funds' jobs boards.